Tesamorelin

About Tesamorelin

Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH) used in research applications studying growth hormone secretion.

This research peptide is supplied as a lyophilized powder that requires reconstitution before use in laboratory applications. It is provided at research-grade purity for in-vitro studies only.

Research Applications: Tesamorelin is used exclusively for laboratory research purposes. It is not intended for human consumption, medical treatment, or any form of in-vivo application.

Storage: Store lyophilized powder at -20°C. After reconstitution, store at 2-8°C and use within the timeframe specified by the manufacturer.

Detailed Research Information

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog studied extensively in metabolic research and lipodystrophy investigations. As a research compound, Tesamorelin is examined for its targeted effects on visceral adipose tissue, metabolic regulation, and growth hormone axis stimulation.

Key Research Applications

Visceral Fat Research: Tesamorelin is utilized in studies investigating mechanisms of visceral adipose tissue reduction, lipid metabolism in intra-abdominal fat deposits, and regional fat distribution regulation.

Lipodystrophy Studies: Research applications include examination of abnormal fat distribution patterns, metabolic complications of lipodystrophy, and interventions targeting ectopic fat accumulation.

Metabolic Syndrome Research: Tesamorelin is employed in studies exploring insulin sensitivity mechanisms, glucose metabolism improvements, and metabolic parameter normalization in obesity models.

IGF-1 Modulation Studies: Research utilizes Tesamorelin to investigate selective IGF-1 elevation, downstream metabolic effects of increased IGF-1 levels, and tissue-specific responses to IGF-1 signaling.

Mechanism of Action

Tesamorelin functions through binding to pituitary GHRH receptors, stimulating endogenous growth hormone production and subsequently elevating IGF-1 levels. The peptide contains a trans-3-hexenoic acid group modification that extends half-life and enhances stability. Research demonstrates that Tesamorelin produces sustained growth hormone elevation leading to preferential reduction in visceral adipose tissue through enhanced lipolysis, possibly mediated by increased beta-adrenergic receptor sensitivity in visceral adipocytes.

Product Specifications

All listed research peptides are supplied in lyophilized (freeze-dried) powder form and require reconstitution with bacteriostatic water or sterile water before use in laboratory applications. Products are intended exclusively for in vitro research and are not for human consumption.